Investing.com UK - Financial Markets Worldwide
⏳ Final hours! Save up to 60% OFF InvestingProCLAIM SALE

Novavax Says Initial 1M Doses Of Nuvaxovid COVID-19 Vaccine Are Available In UK

Published 27/09/2022, 17:48
© Reuters. Novavax Says Initial 1M Doses Of Nuvaxovid COVID-19 Vaccine Are Available In UK
NVAX
-

  • Novavax Inc (NASDAQ: NVAX) announced that an initial one million doses of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine are now available in the U.K.
  • Nuvaxovid is the first protein-based COVID-19 vaccine granted authorization from the Medicines and Healthcare products Regulatory Agency (MHRA). It will be offered per the Joint Committee on Vaccination and Immunisation (JCVI) advice.
  • Related: Europe Backs Approval Of Omicron-Adapted COVID-19 Vaccines.
  • The MHRA granted Conditional Marketing Authorization for Nuvaxovid's use as a two-dose primary series vaccine in adults aged 18 and older in February 2022 and adolescents aged 12 through 17 in August 2022.
  • In August, FDA also granted expanded use authorization for Novavax's COVID-19 vaccine in adolescents.
  • Novavax submitted a request to the MHRA for expanded CMA of Nuvaxovid as a booster in adults aged 18 and older in June and is awaiting a decision from the agency.
  • Price Action: NVAX shares are up 6.41% at $20.08 on the last check Tuesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.